Special Issue

Designing and Developing the Next Generation of Vaccine Adjuvants

Message from the Guest Editors

Over the past two decades, there have been significant advances in the development of novel vaccine adjuvant formulations, building from an improved understanding of how these adjuvants work, and the key role of 'delivery'. This past decade also saw the advance of several new adjuvants into clinical development, and even included into licensed products. These recent advances have expanded our understanding on mechanisms of action and have laid the groundwork for the development of new and improved technologies. There have been significant insights into the identification of new and improved agonists, which can be exploited for the rational development of the next generation of adjuvants—particularly if these ligands can be coupled with improved delivery systems to enhance potency, and limit reactogenicity, or safety concerns. This Special Issue on "Designing and Developing the Next Generation of Vaccine Adjuvants" will focus on highlighting key tools for designing and discovering novel vaccine adjuvants as well as discussing advances made in developing adjuvants suitable for clinical evaluation.

Guest Editors

Dr. Derek T. O'Hagan

GSK, Rockville Center for Vaccines Research, Rockville, MD 20850, USA

Dr. Rushit N. Lodaya

GSK, Rockville Center for Vaccines Research, Rockville, MD 20850, USA

Deadline for manuscript submissions

closed (20 April 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/134317

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

